Molecular characterization of human prostate carcinoma cell lines

This study presents a comprehensive survey and characterization of available prostate carcinoma cell lines, most of which have been widely used but are incompletely characterized.

[1]  F. Schröder,et al.  Human prostatic carcinoma in cell culture: Preliminary report on the development and characterization of an epithelial cell line (EB 33) , 1974, Urological Research.

[2]  M. Lucia,et al.  Spectral karyotype (SKY) analysis of human prostate carcinoma cell lines , 2003, The Prostate.

[3]  H. Miyake,et al.  Establishment of a prostatic small‐cell carcinoma cell line (SO‐MI) , 2003, The Prostate.

[4]  P. Abrahamsson.  Neuroendocrine differentiation in prostatic carcinoma , 1999, The Prostate.

[5]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[6]  C. Tepper,et al.  Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. , 2002, Cancer research.

[7]  I. N. Reid,et al.  Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma , 2002, The Prostate.

[8]  D. Burstein,et al.  P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. , 2002, Human pathology.

[9]  Dean Bok,et al.  Retinol metabolism and lecithin:retinol acyltransferase levels are reduced in cultured human prostate cancer cells and tissue specimens. , 2002, Cancer research.

[10]  J. Schalken,et al.  Expression of basal cell keratins in human prostate cancer metastases and cell lines , 2001, The Journal of pathology.

[11]  M Dietel,et al.  Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. , 2001, American journal of clinical pathology.

[12]  D. Feldman,et al.  The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.

[13]  C. Korch,et al.  TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin. , 2001, Cancer research.

[14]  G. Miller,et al.  Karyotypic similarity identified by multiplex‐FISH relates four prostate adenocarcinoma cell lines: PC‐3, PPC‐1, ALVA‐31, and ALVA‐41 , 2001, Genes, chromosomes & cancer.

[15]  L. Weiss,et al.  Cytokeratin 14 expression in epithelial neoplasms: a survey of 435 cases with emphasis on its value in differentiating squamous cell carcinomas from other epithelial tumours , 2001, Histopathology.

[16]  A. Cress,et al.  PEAZ‐1: A new human prostate neoplastic epithelial cell line , 2001, The Prostate.

[17]  J A Thomson,et al.  Short tandem repeat profiling provides an international reference standard for human cell lines , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  S. Downing,et al.  Mutations within the tumour suppressor gene p53 are not confined to a late event in prostate cancer progression. a review of the evidence. , 2001, Urologic oncology.

[19]  K. Nakashiro,et al.  Androgen receptor expression in androgen‐independent prostate cancer cell lines , 2001, The Prostate.

[20]  C. Korch,et al.  Widely used prostate carcinoma cell lines share common origins , 2001, The Prostate.

[21]  F. S. French,et al.  Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. , 2001, Cancer research.

[22]  K. Pienta,et al.  VCaP, a cell-based model system of human prostate cancer. , 2001, In vivo.

[23]  K. Pienta,et al.  Establishment and characterization of a new human prostatic cancer cell line: DuCaP. , 2001, In vivo.

[24]  C. Larsson,et al.  5q11, 8p11, and 10q22 are recurrent chromosomal breakpoints in prostate cancer cell lines , 2001, Genes, chromosomes & cancer.

[25]  F. Watt,et al.  Epithelial Cell Differentiation Pathways in the Human Prostate: Identification of Intermediate Phenotypes by Keratin Expression , 2001, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[26]  H. Bonkhoff.  Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  R Montironi,et al.  p63 is a prostate basal cell marker and is required for prostate development. , 2000, The American journal of pathology.

[28]  A. Belldegrun,et al.  WISH-PC2: a unique xenograft model of human prostatic small cell carcinoma. , 2000, Cancer research.

[29]  F. Watt,et al.  Proliferative Heterogeneity in the Human Prostate: Evidence for Epithelial Stem Cells , 2000, Laboratory Investigation.

[30]  J. Schalken,et al.  Demonstration of Intermediate Cells during Human Prostate Epithelial Differentiation In Situ and In Vitro Using Triple-Staining Confocal Scanning Microscopy , 2000, Laboratory Investigation.

[31]  D. Peehl,et al.  1α,25-Dihydroxyvitamin D3 Inhibits Prostate Cancer Cell Growth by Androgen-Dependent and Androgen-Independent Mechanisms. , 2000, Endocrinology.

[32]  R. Kushima,et al.  Establishment and characterization of a prostatic small‐cell carcinoma cell line (PSK‐1) derived from a patient with Klinefelter syndrome , 2000, The Prostate.

[33]  K. Pienta,et al.  Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  T. McDonnell,et al.  TabBO: a model reflecting common molecular features of androgen-independent prostate cancer. , 2000, Clinical Cancer Research.

[35]  C. Larsson,et al.  Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping , 2000, Cytogenetic and Genome Research.

[36]  D. Peehl,et al.  Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. , 1999, The Journal of urology.

[37]  W. Isaacs,et al.  DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. , 1999, Cancer research.

[38]  H. Drexler,et al.  Widespread intraspecies cross‐contamination of human tumor cell lines arising at source , 1999, International journal of cancer.

[39]  S. Schwartz,et al.  Molecular cytogenetic studies of a serially transplanted primary prostatic carcinoma xenograft (CWR22) and four relapsed tumors , 1999, The Prostate.

[40]  S. Schwartz,et al.  A new human prostate carcinoma cell line, 22Rv1 , 1999, In Vitro Cellular & Developmental Biology - Animal.

[41]  Ximing J. Yang,et al.  Rare expression of high-molecular-weight cytokeratin in adenocarcinoma of the prostate gland: a study of 100 cases of metastatic and locally advanced prostate cancer. , 1999, The American journal of surgical pathology.

[42]  P. Troncoso,et al.  p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. , 1999, The Journal of urology.

[43]  Ruggero Montesano,et al.  IARC p53 mutation database: A relational database to compile and analyze p53 mutations in human tumors and cell lines , 1999, Human mutation.

[44]  E. Schröck,et al.  Comprehensive and definitive molecular cytogenetic characterization of HeLa cells by spectral karyotyping. , 1999, Cancer research.

[45]  T. H. van der Kwast,et al.  Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer. , 1998, Human pathology.

[46]  N. Hay,et al.  Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. , 1998, Molecular endocrinology.

[47]  M. Varella‐Garcia,et al.  Receptor expression, cytogenetic, and molecular analysis of six continuous human glioma cell lines , 1998, In Vitro Cellular & Developmental Biology - Animal.

[48]  D. Johnston,et al.  Establishment of two human prostate cancer cell lines derived from a single bone metastasis. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  M W Kattan,et al.  Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  K. A. Klein,et al.  Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice , 1997, Nature Medicine.

[51]  K. Hamil,et al.  Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. , 1997, Molecular endocrinology.

[52]  P. Googe,et al.  Anticytokeratin Antibody 34βE12 Staining in Prostate Carcinoma , 1997 .

[53]  J. Trapman,et al.  An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. , 1997, Molecular endocrinology.

[54]  L. Chung,et al.  Androgen-repressed phenotype in human prostate cancer. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[55]  S. Schwartz,et al.  CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. , 1996, Cancer research.

[56]  F. Schröder,et al.  Perspectives of the Use of Tissue Culture Methods as an Alternative to Human Prostate Cancer Xenografts in Nude Mice , 1996 .

[57]  H. Bonkhoff,et al.  Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: A stem cell model , 1996, The Prostate.

[58]  P. Schiller,et al.  Gap‐junctional communication in normal and neoplastic prostate epithelial cells and its regulation by cAMP , 1996, Molecular carcinogenesis.

[59]  P. Roy-Burman,et al.  Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. , 1995, The American journal of pathology.

[60]  S. Schwartz,et al.  CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. , 1994, Cancer research.

[61]  W. Rosner,et al.  Characterization of ALVA-41 cells, a new human prostatic cancer cell line , 1994, Steroids.

[62]  E. Hoal-van Helden,et al.  Detection by DNA fingerprinting of somatic changes during the establishment of a new prostate cell line. , 1994, British Journal of Cancer.

[63]  L. Chung,et al.  Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. , 1994, Cancer research.

[64]  T. Chen,et al.  Chromosome identity of human prostate cancer cell lines, PC-3 and PPC-1. , 1993, Cytogenetics and cell genetics.

[65]  E. Gelmann,et al.  p53 oncogene mutations in three human prostate cancer cell lines , 1993, The Prostate.

[66]  R. Ostenson,et al.  Human primary prostate tumor cell line, ALVA‐31: A new model for studying the hormonal regulation of prostate tumor cell growth , 1993, The Prostate.

[67]  J. Schalken,et al.  Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. , 1992, Cancer research.

[68]  R. Dahiya,et al.  Establishment and characterization of a human primary prostatic adenocarcinoma cell line (ND-1). , 1992, The Journal of urology.

[69]  R. Ostenson,et al.  Effects of sex hormone binding globulin (SHBG) on human prostatic carcinoma , 1991, The Journal of Steroid Biochemistry and Molecular Biology.

[70]  J. Gingrich,et al.  Establishment and characterization of a new human prostatic carcinoma cell line (DuPro-1). , 1991, The Journal of urology.

[71]  W. Isaacs,et al.  Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. , 1991, Cancer research.

[72]  G. Jenster,et al.  A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. , 1990, Biochemical and biophysical research communications.

[73]  J. Addonizio,et al.  Establishment of new human prostatic cancer cell line (JCA-1). , 1990, Urology.

[74]  George L. Wright,et al.  Phenotypic and cytogenetic characterization of a cell line derived from primary prostatic carcinoma , 1989, International journal of cancer.

[75]  S. Naylor,et al.  Retention of chromosome 3 in extrapulmonary small cell cancer shown by molecular and cytogenetic studies. , 1989, Journal of the National Cancer Institute.

[76]  E. Kruse,et al.  Identification by C‐banding of two human prostate tumour cell lines, 1013L and DU 145 , 1989, International journal of cancer.

[77]  K. Fan,et al.  Heterogeneous subpopulations of human prostatic adenocarcinoma cells: potential usefulness of P21 protein as a predictor for bone metastasis. , 1988, The Journal of urology.

[78]  I. Kondo,et al.  Establishment of a new prostatic carcinoma cell line (TSU-Pr1). , 1987, The Journal of urology.

[79]  T. Stamey,et al.  Keratin immunoreactivity in the benign and neoplastic human prostate. , 1985, Cancer research.

[80]  G. Bepler,et al.  Establishment and identification of small cell lung cancer cell lines having classic and variant features. , 1985, Cancer research.

[81]  M. Hida,et al.  Metastatic patterns of prostatic cancer: Correlation between sites and number of organs involved , 1984, Cancer.

[82]  H. Grossman,et al.  UM-SCP-1, a new human cell line derived from a prostatic squamous cell carcinoma. , 1984, Cancer research.

[83]  F. Claas,et al.  Expression of HLA-like structures on a permanent human tumor line PC-93. , 2008, Tissue antigens.

[84]  B. Hill,et al.  In vitro responses of human prostate tumour cell lines to a range of antitumour agents , 1983, International journal of cancer.

[85]  G. Murphy,et al.  LNCaP model of human prostatic carcinoma. , 1983, Cancer research.

[86]  Nelson Wa,et al.  Karyotyping of prostatic carcinoma cell line. , 1978 .

[87]  K. Kuo,et al.  Biochemical markers of cultured human prostatic epithelium. , 1978, The Journal of urology.

[88]  D. Paulson,et al.  Isolation of a human prostate carcinoma cell line (DU 145) , 1978, International journal of cancer.

[89]  R. Vollmer,et al.  Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice. , 1977, Cancer research.

[90]  D. Lubaroff.  Development of an epithelial tissue culture line from human prostatic adenocarcinoma. , 1977, The Journal of urology.

[91]  W. Nelson-Rees,et al.  HeLa cultures defined. , 1976, Science.

[92]  W. Nelson-Rees,et al.  Banded Marker Chromosomes as Indicators of Intraspecies Cellular Contamination , 1974, Science.

[93]  E. Fraley,et al.  Spontaneous in vitro Neoplastic Transformation of Adult Human Prostatic Epithelium , 1970, Science.